Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


June 30, 2015 4:22 PM ET

Pharmaceuticals

Company Overview of FORUM Pharmaceuticals Inc.

Company Overview

FORUM Pharmaceuticals Inc. operates as a biopharmaceutical company focused on the development and delivery of medicines to treat serious brain diseases that include Alzheimer’s disease, schizophrenia, and frontotemporal dementia. Its products include alpha-7 Receptor Response, an orally administered encenicline; PDE 10 program, an investigational phosphodiesterase inhibitor; and Gamma-secretase modulators to correct the loss-of-function defect in familial Alzheimer’s disease caused by genetic mutations in presenilin proteins. The company also develops genetically targeted therapies, including FRM-0334 for the treatment of the ultra-orphan and frontotemporal dementia. FORUM Pharmaceuticals In...

500 Arsenal Street

Watertown, MA 02472

United States

Founded in 2001

Phone:

617-225-4250

Fax:

617-225-5267

Key Executives for FORUM Pharmaceuticals Inc.

Chief Executive Officer, President and Director
Age: 51
Chief Financial Officer and Senior Vice President
Chief Scientific Officer and Senior Vice President of Research
Senior Vice President and General Counsel
Chief Business Officer and Senior Vice President
Age: 52
Compensation as of Fiscal Year 2014.

FORUM Pharmaceuticals Inc. Key Developments

FORUM Pharmaceuticals Inc. Receives U.S. Food and Drug Administration Fast Track Designation for Encenicline to Treat Cognitive Impairment in Schizophrenia

FORUM Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to encenicline, FORUM’s lead compound in development to treat cognitive impairment in schizophrenia. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of drug candidates intended to treat serious or life-threatening conditions, and to demonstrate the potential to address unmet medical needs. Encenicline is a novel alpha 7 agonist in Phase 3 development by FORUM to treat cognitive impairment in schizophrenia and Alzheimer’s disease. The Company recently completed patient enrollment in its pivotal Phase 3 COGNITIV SZ clinical trial program investigating the use of encenicline as a pro-cognitive therapy in patients with schizophrenia who are currently being treated with atypical antipsychotics. The COGNITIV SZ Phase 3 clinical trial program includes two randomized, double-blind, placebo-controlled studies evaluating the safety and efficacy of two oral doses of once daily treatment with encenicline as a pro-cognitive treatment compared to placebo when added to chronic, stable, atypical antipsychotic therapy in people with schizophrenia. Primary endpoints of the trials include effect on cognitive function as measured by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS™) Consensus Cognitive Battery (MCCB™), and effect on clinical function as measured by the interview-based Schizophrenia Cognition Rating Scale (SCoRS). Secondary endpoints of the trial include the clinical efficacy as measured by the negative subscale of the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression – Severity (CGI-S), Clinical Global Impression – Change scale (CGI-C), and quality of life, using the EuroQoL-5D™ (EQ-5D). Safety will be determined by clinical and laboratory safety assessments. The two global 26-week trials enrolled a total of more than 1,500 patients at approximately 200 clinical sites. Encenicline is a novel, orally administered, highly brain-penetrant, selective, and potent agonist of the alpha 7 receptor found in hippocampal and cortical neurons involved in cognition. Encenicline is believed to work in low concentrations to prime the alpha 7 receptor to increase its response to acetylcholine, a naturally occurring neurotransmitter. This effect is thought to activate brain networks associated with sensory gating, attention, and cognition—thus enhancing these networks for improved neural processing and improved cognitive performance in areas such as memory and executive function. Encenicline is in development by FORUM Pharmaceuticals as a long-term treatment to improve cognitive function with sustained effect in schizophrenia and Alzheimer’s disease. In preclinical studies, alpha 7 agonists increased neuronal synchronization and enhanced synaptic plasticity, measured by an increase in long term potentiation (LTP). These effects may be linked to enhanced cognition not only in Alzheimer’s disease and schizophrenia, but suggest potential in other diseases with cognitive impairment. Encenicline is the first alpha 7 agonist drug candidate to reach pivotal Phase 3 development. Two Phase 3 registration multi-center clinical trials (COGNITIV SZ) investigating the use of encenicline for cognitive impairment in schizophrenia have recently completed enrollment (www.clinicaltrials.gov registration numbers NCT01714661 and NCT01716975). Additionally, FORUM is investigating the use of encenicline for Alzheimer’s disease through a Special Protocol Assessment with the FDA. Two Phase 3 registration multi-center trials (COGNITIV AD) investigating the use of encenicline for Alzheimer’s disease are ongoing (www.clinicaltrials.gov registration numbers NCT01969123 and NCT01969136). FORUM has a license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of encenicline in Alzheimer’s disease in Japan and several other Asian countries. Schizophrenia is a psychiatric disorder that affects approximately 2.2 million Americans, or about 1% of the adult population worldwide, and is usually diagnosed between 15 and 35 years of age. Symptoms of schizophrenia typically include positive and negative symptoms and cognitive impairment. “Positive” symptoms include hallucinations, delusions and paranoia. “Negative” symptoms include loss of motivation and interest in everyday activities, blunting of emotion, decrease in speech and social withdrawal. Cognitive impairments such as difficulty in attention, memory loss and problems processing information and decision-making are recognized as core disabling symptoms of schizophrenia linked to the functional impairment in this condition. The overall annual cost of schizophrenia in the U.S. is estimated at more than $62 billion, according to a study published in the Journal of Clinical Psychiatry.

FORUM Pharmaceuticals Inc. Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial Program of Encenicline for Cognitive Impairment in Schizophrenia

FORUM Pharmaceuticals Inc. announced the completion of patient enrollment in its two pivotal Phase 3 clinical trials investigating the use of encenicline to treat cognitive impairment in schizophrenia. The Phase 3 clinical trial program, known as COGNITIV SZ, is designed to assess the safety and efficacy of encenicline compared to placebo as a pro-cognitive therapy in patients with schizophrenia treated with atypical antipsychotics. Each of the two 26-week multinational trials enrolled more than 750 patients. Encenicline is a novel alpha 7 agonist in Phase 3 development by FORUM to treat cognitive impairment in schizophrenia and Alzheimer’s disease.

FORUM Pharmaceuticals Inc. Presents at BIO International Convention 2015, Jun-15-2015 through Jun-18-2015

FORUM Pharmaceuticals Inc. Presents at BIO International Convention 2015, Jun-15-2015 through Jun-18-2015. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Presentation Date & Speakers: Jun-16-2015, Baruch Harris, Senior Director, Corporate Development and Investor Relations, Gerhard Koenig, Chief Scientific Officer and Senior Vice President of Research.

Similar Private Companies By Industry

Company Name Region
Johnson & Johnson International, Inc. United States
By-Prod Corporation United States
Blend Therapeutics, Inc. United States
Intervet, Inc. United States
Heritage Consumer Products, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FORUM Pharmaceuticals Inc., please visit www.forumpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.